부산대학교 도서관

STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with either Autistic Disorder or Pervasive Developmental Disorder--Not Otherwise Specified, and a score [greater than or equal to]17 on the Aberrant Behavior Checklist (ABC)--Irritability subscale. STX209 was generally well-tolerated. The most common adverse events were agitation and irritability, which typically resolved without dose changes, and were often felt to represent spontaneous variation in underlying symptoms. Improvements were observed on several outcome measures in this exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCSPDD, and clinical global impression scales. Placebo-controlled study of STX209 is warranted. Keywords STX209 * Arbaclofen * Gamma-aminobutyric acid (GABA) * Autism spectrum disorder * Clinical trial
Introduction Although the number of children and adults diagnosed with autism spectrum disorders (ASD) has increased over the last decade, (CDC 2012) only two pharmacologic agents (risperidone and aripiprazole) are [...]